SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations

SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of a...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 5171 - 11
Main Authors Hederman, Andrew P., Natarajan, Harini, Heyndrickx, Leo, Ariën, Kevin K., Wiener, Joshua A., Wright, Peter F., Bloch, Evan M., Tobian, Aaron A. R., Redd, Andrew D., Blankson, Joel N., Rottenstreich, Amihai, Zarbiv, Gila, Wolf, Dana, Goetghebuer, Tessa, Marchant, Arnaud, Ackerman, Margaret E.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 24.08.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text
ISSN2041-1723
2041-1723
DOI10.1038/s41467-023-40960-0

Cover

Abstract SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve. As the SARS-SoV-2 pandemic progressed and the vaccinated population increased, a number of variants of concerns that circumvented the vaccine induced immunity emerged. Here the authors compare SARS-SoV-2 mRNA vaccine responses in pregnant women and other people, characterising the antibody response and Fc functions, and potency against a range of variants of concern.
AbstractList SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve. As the SARS-SoV-2 pandemic progressed and the vaccinated population increased, a number of variants of concerns that circumvented the vaccine induced immunity emerged. Here the authors compare SARS-SoV-2 mRNA vaccine responses in pregnant women and other people, characterising the antibody response and Fc functions, and potency against a range of variants of concern.
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.As the SARS-SoV-2 pandemic progressed and the vaccinated population increased, a number of variants of concerns that circumvented the vaccine induced immunity emerged. Here the authors compare SARS-SoV-2 mRNA vaccine responses in pregnant women and other people, characterising the antibody response and Fc functions, and potency against a range of variants of concern.
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
Abstract SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other antibody functions are similarly compromised, or if they might compensate for lost neutralization activity. Here, the breadth and potency of antibody recognition and effector function is surveyed following either infection or vaccination. Considering pregnant women as a model cohort with higher risk of severe illness and death, we observe similar binding and functional breadth for healthy and immunologically vulnerable populations, but considerably greater functional antibody breadth and potency across variants associated with vaccination. In contrast, greater antibody functional activity targeting the endemic coronavirus OC43 is noted among convalescent individuals, illustrating a dichotomy in recognition between close and distant human coronavirus strains associated with exposure history. This analysis of antibody functions suggests the differential potential for antibody effector functions to contribute to protecting vaccinated and convalescent subjects as novel variants continue to evolve.
ArticleNumber 5171
Author Redd, Andrew D.
Wolf, Dana
Wiener, Joshua A.
Hederman, Andrew P.
Wright, Peter F.
Blankson, Joel N.
Goetghebuer, Tessa
Ariën, Kevin K.
Natarajan, Harini
Rottenstreich, Amihai
Zarbiv, Gila
Bloch, Evan M.
Ackerman, Margaret E.
Tobian, Aaron A. R.
Marchant, Arnaud
Heyndrickx, Leo
Author_xml – sequence: 1
  givenname: Andrew P.
  surname: Hederman
  fullname: Hederman, Andrew P.
  organization: Thayer School of Engineering, Dartmouth College
– sequence: 2
  givenname: Harini
  surname: Natarajan
  fullname: Natarajan, Harini
  organization: Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth College
– sequence: 3
  givenname: Leo
  surname: Heyndrickx
  fullname: Heyndrickx, Leo
  organization: Department of Biomedical Sciences, Institute of Tropical Medicine
– sequence: 4
  givenname: Kevin K.
  orcidid: 0000-0002-1340-4165
  surname: Ariën
  fullname: Ariën, Kevin K.
  organization: Department of Biomedical Sciences, Institute of Tropical Medicine
– sequence: 5
  givenname: Joshua A.
  orcidid: 0000-0003-1054-0628
  surname: Wiener
  fullname: Wiener, Joshua A.
  organization: Thayer School of Engineering, Dartmouth College
– sequence: 6
  givenname: Peter F.
  surname: Wright
  fullname: Wright, Peter F.
  organization: Department of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center
– sequence: 7
  givenname: Evan M.
  orcidid: 0000-0001-8181-9517
  surname: Bloch
  fullname: Bloch, Evan M.
  organization: Department of Pathology, Johns Hopkins School of Medicine
– sequence: 8
  givenname: Aaron A. R.
  surname: Tobian
  fullname: Tobian, Aaron A. R.
  organization: Department of Pathology, Johns Hopkins School of Medicine
– sequence: 9
  givenname: Andrew D.
  surname: Redd
  fullname: Redd, Andrew D.
  organization: Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
– sequence: 10
  givenname: Joel N.
  surname: Blankson
  fullname: Blankson, Joel N.
  organization: Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine
– sequence: 11
  givenname: Amihai
  surname: Rottenstreich
  fullname: Rottenstreich, Amihai
  organization: Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center
– sequence: 12
  givenname: Gila
  surname: Zarbiv
  fullname: Zarbiv, Gila
  organization: Clinical Virology Unit, Hadassah University Medical Center
– sequence: 13
  givenname: Dana
  surname: Wolf
  fullname: Wolf, Dana
  organization: Clinical Virology Unit, Hadassah University Medical Center
– sequence: 14
  givenname: Tessa
  orcidid: 0000-0002-8809-1394
  surname: Goetghebuer
  fullname: Goetghebuer, Tessa
  organization: Institute for Medical Immunology, Université libre de Bruxelles, Pediatric Department, CHU St Pierre
– sequence: 15
  givenname: Arnaud
  surname: Marchant
  fullname: Marchant, Arnaud
  organization: Institute for Medical Immunology, Université libre de Bruxelles
– sequence: 16
  givenname: Margaret E.
  orcidid: 0000-0002-4253-3476
  surname: Ackerman
  fullname: Ackerman, Margaret E.
  email: margaret.e.ackerman@dartmouth.edu
  organization: Thayer School of Engineering, Dartmouth College, Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Dartmouth College
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37620337$$D View this record in MEDLINE/PubMed
BookMark eNqNks1u1DAUhSNUREvpC7BAltiwCfgvsbNC1QhKpUpIFNhazo0zeOSxg51MNRIPX89kKG0XFdnEcs75fHKPXxZHPnhTFK8Jfk8wkx8SJ7wWJaas5LipcYmfFScUc1ISQdnRvfVxcZbSCueHNURy_qI4ZqKmmDFxUvy5Pv92XS7Cz5KijQawXo82eGScBTsm1MagO6R9h4YwGj_m5Wjb0G2R6XsDY4ionzzsPAmNITOizZKEQo8geDDRI-vRZnLeRN06kznD5PaHpFfF8167ZM4O79Pix-dP3xdfyquvF5eL86sSKk7GEvoGA3S9roQWuqEdtKLmGATpiGakpoQDNcC7RmgGjIoWMOmlFCApkJax0-Jy5nZBr9QQ7VrHrQraqv1GiEul42jBGQXG5ENkz0Vb8UqCFBoErQ3RddPIrs4sNrMmP-jtjXbuDkiw2lWj5mpUrkbtq1E4uz7OrmFq16aDPMmo3YMoD794-0stwyYDOW8asiO8OxBi-D2ZNKq1TWCc096EKSkqKyGZrKpdxLePpKswRZ8nvFPVddVIWWXVm_uR7rL8vRtZIGcBxJBSNL3KN2JfXE5o3dO_Sx9Z_2tGh8mmLPZLE__FfsJ1C1PH79A
CitedBy_id crossref_primary_10_1002_bit_28826
crossref_primary_10_3390_vaccines12101089
crossref_primary_10_1038_s44298_024_00067_9
crossref_primary_10_1002_anie_202404880
crossref_primary_10_1002_ange_202404880
Cites_doi 10.1016/j.cell.2021.12.046
10.1038/s41586-021-03324-6
10.1016/j.cell.2021.06.005
10.1038/s41586-020-2349-y
10.1056/NEJMoa2034577
10.3389/fimmu.2014.00520
10.1016/j.jim.2010.12.016
10.1016/j.immuni.2021.08.015
10.1016/j.celrep.2021.108890
10.1016/j.cell.2021.02.037
10.1128/mbio.03617-21
10.1016/j.jim.2012.09.007
10.1126/science.abj4176
10.1146/annurev-med-042420-113838
10.1016/j.cell.2022.01.019
10.1038/s41591-021-01540-1
10.1093/ofid/ofab143
10.1016/j.cell.2021.02.026
10.1016/j.cell.2020.02.058
10.1016/j.jim.2017.01.010
10.1126/science.1187659
10.1016/j.cell.2021.03.013
10.1056/NEJMoa2022483
10.1038/s41586-021-03791-x
10.1371/journal.ppat.1008764
10.1016/j.cell.2022.01.015
10.1126/scitranslmed.abi8631
10.1038/s41586-021-04017-w
10.1126/science.1118948
10.1056/NEJMoa2035389
10.1016/j.chom.2021.11.006
10.1126/scitranslmed.abm3151
10.1056/NEJMc2113891
10.1056/NEJMc2119912
10.1038/s41586-021-03398-2
10.4161/mabs.28808
10.1038/s41541-022-00459-z
10.1016/j.immuni.2022.01.001
10.1038/s41591-021-01294-w
10.1016/j.cell.2020.10.052
10.1038/s41591-020-0897-1
10.1016/j.xcrm.2021.100290
10.1038/s41586-021-04085-y
10.1126/sciimmunol.abj1750
10.1016/j.celrep.2020.107624
10.1038/s41591-022-01753-y
10.3389/fmed.2021.628370
10.3389/fimmu.2020.618685
10.1038/s41591-018-0161-0
10.1016/j.jim.2018.01.013
10.1038/s41586-021-03696-9
10.1056/NEJMc2119641
10.1016/j.cell.2021.03.029
10.1016/j.xcrm.2021.100355
10.1371/journal.pone.0253487
10.1016/j.immuni.2021.03.009
10.48550/arXiv.1802.03426
10.1126/sciimmunol.abo3425
10.1126/sciimmunol.abe0240
10.1126/sciimmunol.adf1421
10.1016/j.jim.2019.07.002
10.1126/scitranslmed.abb4757
10.1038/s41591-021-01488-2
10.1038/s41586-020-2456-9
10.1016/j.xpro.2021.100851
10.1126/science.abf4063
10.1126/science.abq1841
10.1016/j.chom.2022.03.029
10.7554/eLife.75228
10.1016/j.chom.2021.06.001
10.1126/scitranslmed.abn7842
10.1126/science.abn7591
10.1126/science.abd0826
10.1016/j.celrep.2022.110368
10.1016/j.cell.2020.06.025
10.15585/mmwr.mm6925a1
10.1126/scitranslmed.abm2311
ContentType Journal Article
Copyright The Author(s) 2023
2023. Springer Nature Limited.
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Springer Nature Limited 2023
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. Springer Nature Limited.
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Springer Nature Limited 2023
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1038/s41467-023-40960-0
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Biological Science Database
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE


MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Open Access Full Text
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 6
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 11
ExternalDocumentID oai_doaj_org_article_cee7a78f47b5458c87ac726e1a6998d6
10.1038/s41467-023-40960-0
PMC10449910
37620337
10_1038_s41467_023_40960_0
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: 1U19AI145825; R01AI120938; R01AI120938S1; R01AI128779
  funderid: https://doi.org/10.13039/100000060
– fundername: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
  grantid: P30 CA 023108-41
  funderid: https://doi.org/10.13039/100000054
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
  grantid: P20-GM113132
  funderid: https://doi.org/10.13039/100000057
– fundername: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  grantid: K23HL151826
  funderid: https://doi.org/10.13039/100000050
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
– fundername: NIAID NIH HHS
  grantid: HHSN272201400008C
– fundername: NIGMS NIH HHS
  grantid: P20 GM113132
– fundername: NCI NIH HHS
  grantid: P30 CA023108
– fundername: NIAID NIH HHS
  grantid: R01 AI120938
– fundername: NIAID NIH HHS
  grantid: U19 AI145825
– fundername: NIAID NIH HHS
  grantid: R01 AI128779
– fundername: NHLBI NIH HHS
  grantid: K23 HL151826
– fundername: ;
– fundername: ;
  grantid: P30 CA 023108-41
– fundername: ;
  grantid: P20-GM113132
– fundername: ;
  grantid: 1U19AI145825; R01AI120938; R01AI120938S1; R01AI128779
– fundername: ;
  grantid: K23HL151826
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LGEZI
LK8
LOTEE
M1P
M48
M7P
M~E
NADUK
NAO
NXXTH
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AARCD
AZQEC
C1K
COVID
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
SOI
7X8
5PM
4.4
ADTOC
BAPOH
CAG
COF
EJD
UNPAY
ID FETCH-LOGICAL-c541t-cf90ccdfa57a7a92dcb7640c71d1a316214c2ec4d97a3c327bc01f887c82c1b33
IEDL.DBID UNPAY
ISSN 2041-1723
IngestDate Wed Aug 27 01:33:00 EDT 2025
Wed Oct 01 16:53:37 EDT 2025
Tue Sep 30 17:11:48 EDT 2025
Fri Sep 05 03:29:08 EDT 2025
Wed Aug 13 04:10:15 EDT 2025
Mon Jul 21 05:43:26 EDT 2025
Wed Oct 01 02:52:31 EDT 2025
Thu Apr 24 22:51:37 EDT 2025
Fri Feb 21 02:39:59 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. Springer Nature Limited.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-cf90ccdfa57a7a92dcb7640c71d1a316214c2ec4d97a3c327bc01f887c82c1b33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-8809-1394
0000-0001-8181-9517
0000-0003-1054-0628
0000-0002-1340-4165
0000-0002-4253-3476
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.nature.com/articles/s41467-023-40960-0.pdf
PMID 37620337
PQID 2856659885
PQPubID 546298
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_cee7a78f47b5458c87ac726e1a6998d6
unpaywall_primary_10_1038_s41467_023_40960_0
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10449910
proquest_miscellaneous_2857838556
proquest_journals_2856659885
pubmed_primary_37620337
crossref_citationtrail_10_1038_s41467_023_40960_0
crossref_primary_10_1038_s41467_023_40960_0
springer_journals_10_1038_s41467_023_40960_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-08-24
PublicationDateYYYYMMDD 2023-08-24
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-24
  day: 24
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Wang (CR14) 2022; 13
Tseng (CR62) 2022; 28
Gunn (CR32) 2021; 54
Dan (CR20) 2021; 371
Muik (CR53) 2022; 375
Butler (CR81) 2021; 11
Ellington (CR47) 2020; 69
Arunachalam (CR17) 2021; 596
Bowen (CR58) 2022; 7
Zhou (CR10) 2021; 184
Walls (CR56) 2020; 181
Wu (CR76) 2010; 329
Tarke (CR16) 2021; 2
Brown (CR74) 2012; 386
Om (CR68) 2020; 16
Richardson (CR26) 2022; 30
Amanat (CR15) 2021; 184
Tauzin (CR28) 2021; 29
Wang (CR9) 2021; 593
Chen (CR13) 2021; 27
Adeniji (CR25) 2021; 12
Polack (CR3) 2020; 383
CR49
Ackerman (CR65) 2018; 24
Miller-Novak (CR67) 2018; 92
Ullah (CR36) 2021; 54
Pajon (CR52) 2022; 386
Bégin (CR70) 2021; 27
Zohar (CR11) 2020; 183
Suryadevara (CR38) 2021; 184
Lee (CR60) 2022; 376
Anand (CR82) 2021; 2
Cui (CR40) 2022; 185
Hsieh (CR63) 2020; 369
Li, Sempowski, Saunders, Acharya, Haynes (CR37) 2022; 73
Atyeo (CR48) 2021; 13
Zohar (CR33) 2022; 30
Bates (CR43) 2021; 12
Feng (CR12) 2021; 27
Garcia-Beltran (CR29) 2021; 184
Baden (CR1) 2021; 384
Windsor (CR21) 2022; 7
Robbiani (CR46) 2020; 584
Boesch (CR73) 2014; 6
Fischinger (CR84) 2019; 473
Redd (CR23) 2021; 8
Wang (CR42) 2021; 595
Felber (CR66) 2020; 31
Rees-Spear (CR7) 2021; 34
CR55
Ackerman (CR80) 2011; 366
Wang (CR57) 2022; 13
Wang (CR6) 2021; 592
Pegu (CR4) 2021; 373
Dejnirattisai (CR41) 2022; 185
Tarke (CR19) 2022; 185
Long (CR44) 2020; 26
Dias (CR31) 2022; 14
Sievers (CR5) 2022; 14
Lucas (CR30) 2021; 600
Suscovich (CR69) 2020; 12
Chan (CR71) 2021; 16
Kaplonek (CR35) 2022; 55
Jackson (CR2) 2020; 383
Schmidt (CR8) 2022; 386
Kaplonek (CR54) 2022; 14
Yamin (CR72) 2021; 599
Winkler (CR27) 2021; 184
Chung (CR34) 2014; 6
Crowley (CR59) 2022; 11
Beaudoin-Bussières (CR24) 2022; 38
Reynolds (CR64) 2022; 377
Geers (CR18) 2021; 6
Brown (CR77) 2017; 443
Röltgen (CR45) 2020; 5
Redd (CR22) 2022; 13
Pinto (CR75) 2020; 583
Arien (CR79) 2022; 7
Beaudoin-Bussieres, Richard, Prevost, Goyette, Finzi (CR83) 2021; 2
Nimmerjahn, Ravetch (CR50) 2005; 310
Zauche (CR61) 2021; 385
Barnes (CR39) 2020; 182
Vidarsson, Dekkers, Rispens (CR51) 2014; 5
Brown (CR78) 2018; 455
LR Baden (40960_CR1) 2021; 384
A Pegu (40960_CR4) 2021; 373
F Amanat (40960_CR15) 2021; 184
JM Dan (40960_CR20) 2021; 371
BM Gunn (40960_CR32) 2021; 54
CO Barnes (40960_CR39) 2020; 182
40960_CR49
C Wang (40960_CR57) 2022; 13
OS Adeniji (40960_CR25) 2021; 12
S Fischinger (40960_CR84) 2019; 473
D Geers (40960_CR18) 2021; 6
P Kaplonek (40960_CR35) 2022; 55
ME Ackerman (40960_CR80) 2011; 366
P Kaplonek (40960_CR54) 2022; 14
F Schmidt (40960_CR8) 2022; 386
C Rees-Spear (40960_CR7) 2021; 34
LH Zauche (40960_CR61) 2021; 385
EP Brown (40960_CR77) 2017; 443
K Röltgen (40960_CR45) 2020; 5
LA Jackson (40960_CR2) 2020; 383
AR Crowley (40960_CR59) 2022; 11
R Yamin (40960_CR72) 2021; 599
I Ullah (40960_CR36) 2021; 54
WF Garcia-Beltran (40960_CR29) 2021; 184
G Vidarsson (40960_CR51) 2014; 5
CEZ Chan (40960_CR71) 2021; 16
A Tarke (40960_CR16) 2021; 2
W Dejnirattisai (40960_CR41) 2022; 185
SI Richardson (40960_CR26) 2022; 30
T Zohar (40960_CR33) 2022; 30
A Muik (40960_CR53) 2022; 375
P Bégin (40960_CR70) 2021; 27
Z Wang (40960_CR42) 2021; 595
Z Wang (40960_CR6) 2021; 592
PS Arunachalam (40960_CR17) 2021; 596
TA Bates (40960_CR43) 2021; 12
S Ellington (40960_CR47) 2020; 69
N Suryadevara (40960_CR38) 2021; 184
A Tauzin (40960_CR28) 2021; 29
EP Brown (40960_CR74) 2012; 386
G Beaudoin-Bussieres (40960_CR83) 2021; 2
AD Redd (40960_CR23) 2021; 8
LK Miller-Novak (40960_CR67) 2018; 92
TJ Suscovich (40960_CR69) 2020; 12
Z Cui (40960_CR40) 2022; 185
F Nimmerjahn (40960_CR50) 2005; 310
AD Redd (40960_CR22) 2022; 13
L Wang (40960_CR14) 2022; 13
BL Sievers (40960_CR5) 2022; 14
S Feng (40960_CR12) 2021; 27
A Tarke (40960_CR19) 2022; 185
BK Felber (40960_CR66) 2020; 31
D Pinto (40960_CR75) 2020; 583
K Om (40960_CR68) 2020; 16
AW Boesch (40960_CR73) 2014; 6
RE Chen (40960_CR13) 2021; 27
D Li (40960_CR37) 2022; 73
SE Butler (40960_CR81) 2021; 11
KK Arien (40960_CR79) 2022; 7
C Atyeo (40960_CR48) 2021; 13
AW Chung (40960_CR34) 2014; 6
R Pajon (40960_CR52) 2022; 386
ARYB Lee (40960_CR60) 2022; 376
EP Brown (40960_CR78) 2018; 455
HF Tseng (40960_CR62) 2022; 28
G Beaudoin-Bussières (40960_CR24) 2022; 38
T Zohar (40960_CR11) 2020; 183
IW Windsor (40960_CR21) 2022; 7
40960_CR55
CL Hsieh (40960_CR63) 2020; 369
X Wu (40960_CR76) 2010; 329
SP Anand (40960_CR82) 2021; 2
AC Walls (40960_CR56) 2020; 181
DF Robbiani (40960_CR46) 2020; 584
D Zhou (40960_CR10) 2021; 184
Q-X Long (40960_CR44) 2020; 26
AG Dias Jr (40960_CR31) 2022; 14
JE Bowen (40960_CR58) 2022; 7
FP Polack (40960_CR3) 2020; 383
CJ Reynolds (40960_CR64) 2022; 377
P Wang (40960_CR9) 2021; 593
ES Winkler (40960_CR27) 2021; 184
C Lucas (40960_CR30) 2021; 600
ME Ackerman (40960_CR65) 2018; 24
36172122 - medRxiv. 2022 Sep 18:2022.09.15.22280000. doi: 10.1101/2022.09.15.22280000
References_xml – volume: 6
  start-page: 228ra238
  year: 2014
  ident: CR34
  article-title: Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 Vaccines
  publication-title: Sci. Transl. Med.
– volume: 181
  start-page: 281
  year: 2020
  end-page: 292.e286
  ident: CR56
  article-title: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein
  publication-title: Cell
– volume: 184
  start-page: 2316
  year: 2021
  end-page: 2331.e2315
  ident: CR38
  article-title: Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
  publication-title: Cell
– volume: 386
  start-page: 117
  year: 2012
  end-page: 123
  ident: CR74
  article-title: High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples
  publication-title: J. Immunol. Methods
– ident: CR49
– volume: 6
  start-page: eabj1750
  year: 2021
  ident: CR18
  article-title: SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
  publication-title: Sci. Immunol.
– volume: 31
  start-page: 107624
  year: 2020
  ident: CR66
  article-title: Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge
  publication-title: Cell Rep.
– volume: 596
  start-page: 410
  year: 2021
  end-page: 416
  ident: CR17
  article-title: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
  publication-title: Nature
– volume: 329
  start-page: 856
  year: 2010
  end-page: 861
  ident: CR76
  article-title: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
  publication-title: Science
– volume: 14
  start-page: eabm3151
  year: 2022
  ident: CR31
  article-title: Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection
  publication-title: Sci. Transl. Med.
– volume: 383
  start-page: 2603
  year: 2020
  end-page: 2615
  ident: CR3
  article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
  publication-title: N. Engl. J. Med.
– volume: 12
  start-page: eabb4757
  year: 2020
  ident: CR69
  article-title: Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination
  publication-title: Sci. Transl. Med.
– volume: 183
  start-page: 1508
  year: 2020
  end-page: 1519.e1512
  ident: CR11
  article-title: Compromised humoral functional evolution tracks with SARS-CoV-2 mortality
  publication-title: Cell
– volume: 366
  start-page: 8
  year: 2011
  end-page: 19
  ident: CR80
  article-title: A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
  publication-title: J. Immunol. Methods
– volume: 2
  start-page: 100290
  year: 2021
  ident: CR82
  article-title: Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
  publication-title: Cell Rep. Med.
– volume: 185
  start-page: 860
  year: 2022
  end-page: 871.e813
  ident: CR40
  article-title: Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
  publication-title: Cell
– volume: 16
  start-page: e0253487
  year: 2021
  ident: CR71
  article-title: The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody
  publication-title: PLoS ONE
– volume: 377
  start-page: eabq1841
  year: 2022
  ident: CR64
  article-title: Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
  publication-title: Science
– volume: 34
  start-page: 108890
  year: 2021
  ident: CR7
  article-title: The effect of spike mutations on SARS-CoV-2 neutralization
  publication-title: Cell Rep.
– volume: 184
  start-page: 2372
  year: 2021
  end-page: 2383.e2379
  ident: CR29
  article-title: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
  publication-title: Cell
– volume: 11
  start-page: e75228
  year: 2022
  ident: CR59
  article-title: Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
  publication-title: Elife
– volume: 595
  start-page: 426
  year: 2021
  end-page: 431
  ident: CR42
  article-title: Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
  publication-title: Nature
– volume: 29
  start-page: 1137
  year: 2021
  end-page: 1150.e1136
  ident: CR28
  article-title: A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
  publication-title: Cell Host Microbe
– volume: 12
  start-page: e00281
  year: 2021
  end-page: 21
  ident: CR25
  article-title: COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions
  publication-title: mBio
– volume: 584
  start-page: 437
  year: 2020
  end-page: 442
  ident: CR46
  article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals
  publication-title: Nature
– volume: 12
  year: 2021
  ident: CR43
  article-title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
  publication-title: Nat. Commun.
– volume: 27
  start-page: 717
  year: 2021
  end-page: 726
  ident: CR13
  article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
  publication-title: Nat. Med.
– volume: 24
  start-page: 1590
  year: 2018
  end-page: 1598
  ident: CR65
  article-title: Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV
  publication-title: Nat. Med.
– volume: 69
  start-page: 769
  year: 2020
  end-page: 775
  ident: CR47
  article-title: Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22-June 7, 2020
  publication-title: MMWR Morb. Mortal. Wkly Rep.
– volume: 13
  year: 2022
  ident: CR57
  article-title: Antigenic structure of the human coronavirus OC43 spike reveals exposed and occluded neutralizing epitopes
  publication-title: Nat. Commun.
– volume: 28
  start-page: 1063
  year: 2022
  end-page: 1071
  ident: CR62
  article-title: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
  publication-title: Nat. Med.
– volume: 185
  start-page: 847
  year: 2022
  end-page: 859.e811
  ident: CR19
  article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
  publication-title: Cell
– volume: 182
  start-page: 828
  year: 2020
  end-page: 842.e816
  ident: CR39
  article-title: Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
  publication-title: Cell
– volume: 11
  start-page: 618685
  year: 2021
  ident: CR81
  article-title: Distinct features and functions of systemic and mucosal humoral immunity among SARS-CoV-2 convalescent individuals
  publication-title: Front. Immunol.
– volume: 13
  start-page: e0361721
  year: 2022
  ident: CR22
  article-title: Minimal crossover between mutations associated with omicron variant of SARS-CoV-2 and CD8(+) T-cell epitopes identified in COVID-19 convalescent individuals
  publication-title: mBio
– volume: 6
  start-page: 915
  year: 2014
  end-page: 927
  ident: CR73
  article-title: Highly parallel characterization of IgG Fc binding interactions
  publication-title: MAbs
– volume: 14
  start-page: eabm2311
  year: 2022
  ident: CR54
  article-title: mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
  publication-title: Sci. Transl. Med.
– volume: 369
  start-page: 1501
  year: 2020
  end-page: 1505
  ident: CR63
  article-title: Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
  publication-title: Science
– volume: 7
  start-page: eabo3425
  year: 2022
  ident: CR21
  article-title: Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1
  publication-title: Sci. Immunol.
– volume: 13
  start-page: eabi8631
  year: 2021
  ident: CR48
  article-title: COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women
  publication-title: Sci. Transl. Med.
– volume: 600
  start-page: 523
  year: 2021
  end-page: 529
  ident: CR30
  article-title: Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
  publication-title: Nature
– volume: 385
  start-page: 1533
  year: 2021
  end-page: 1535
  ident: CR61
  article-title: Receipt of mRNA Covid-19 vaccines and risk of spontaneous abortion
  publication-title: N. Engl. J. Med.
– volume: 373
  start-page: 1372
  year: 2021
  end-page: 1377
  ident: CR4
  article-title: Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
  publication-title: Science
– volume: 73
  start-page: 1
  year: 2022
  end-page: 16
  ident: CR37
  article-title: SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
  publication-title: Annu. Rev. Med.
– volume: 583
  start-page: 290
  year: 2020
  end-page: 295
  ident: CR75
  article-title: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
  publication-title: Nature
– volume: 5
  start-page: 520
  year: 2014
  ident: CR51
  article-title: IgG subclasses and allotypes: from structure to effector functions
  publication-title: Front. Immunol.
– volume: 371
  start-page: eabf4063
  year: 2021
  ident: CR20
  article-title: Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
  publication-title: Science
– volume: 5
  start-page: eabe0240
  year: 2020
  ident: CR45
  article-title: Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome
  publication-title: Sci. Immunol.
– volume: 2
  start-page: 100355
  year: 2021
  ident: CR16
  article-title: Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals
  publication-title: Cell Rep. Med.
– volume: 184
  start-page: 1804
  year: 2021
  end-page: 1820.e1816
  ident: CR27
  article-title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
  publication-title: Cell
– volume: 599
  start-page: 465
  year: 2021
  end-page: 470
  ident: CR72
  article-title: Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
  publication-title: Nature
– volume: 593
  start-page: 130
  year: 2021
  end-page: 135
  ident: CR9
  article-title: Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
  publication-title: Nature
– volume: 592
  start-page: 616
  year: 2021
  end-page: 622
  ident: CR6
  article-title: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
  publication-title: Nature
– volume: 310
  start-page: 1510
  year: 2005
  end-page: 1512
  ident: CR50
  article-title: Divergent immunoglobulin g subclass activity through selective Fc receptor binding
  publication-title: Science
– volume: 384
  start-page: 403
  year: 2021
  end-page: 416
  ident: CR1
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine
  publication-title: N. Engl. J. Med.
– volume: 2
  start-page: 100851
  year: 2021
  ident: CR83
  article-title: A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells
  publication-title: STAR Protoc.
– volume: 7
  year: 2022
  ident: CR79
  article-title: Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant
  publication-title: NPJ Vaccines
– volume: 30
  start-page: 41
  year: 2022
  end-page: 52.e45
  ident: CR33
  article-title: Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates
  publication-title: Cell Host Microbe
– volume: 473
  start-page: 112630
  year: 2019
  ident: CR84
  article-title: A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation
  publication-title: J. Immunol. Methods
– volume: 383
  start-page: 1920
  year: 2020
  end-page: 1931
  ident: CR2
  article-title: An mRNA vaccine against SARS-CoV-2—preliminary report
  publication-title: N. Engl. J. Med.
– volume: 55
  start-page: 355
  year: 2022
  end-page: 365.e354
  ident: CR35
  article-title: mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern
  publication-title: Immunity
– volume: 375
  start-page: 678
  year: 2022
  end-page: 680
  ident: CR53
  article-title: Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera
  publication-title: Science
– volume: 92
  start-page: e00721
  year: 2018
  end-page: 18
  ident: CR67
  article-title: Analysis of complement-mediated lysis of simian immunodeficiency virus (SIV) and SIV-infected cells reveals sex differences in vaccine-induced immune responses in
  publication-title: J. Virol.
– volume: 26
  start-page: 845
  year: 2020
  end-page: 848
  ident: CR44
  article-title: Antibody responses to SARS-CoV-2 in patients with COVID-19
  publication-title: Nat. Med.
– volume: 38
  start-page: 110368
  year: 2022
  ident: CR24
  article-title: A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
  publication-title: Cell Rep.
– volume: 184
  start-page: 2348
  year: 2021
  end-page: 2361.e2346
  ident: CR10
  article-title: Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
  publication-title: Cell
– volume: 27
  start-page: 2032
  year: 2021
  end-page: 2040
  ident: CR12
  article-title: Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
  publication-title: Nat. Med.
– volume: 54
  start-page: 2143
  year: 2021
  end-page: 2158.e2115
  ident: CR36
  article-title: Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
  publication-title: Immunity
– volume: 16
  start-page: e1008764
  year: 2020
  ident: CR68
  article-title: Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge
  publication-title: PLoS Pathog.
– volume: 14
  start-page: eabn7842
  year: 2022
  ident: CR5
  article-title: Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
  publication-title: Sci. Transl. Med.
– volume: 386
  start-page: 599
  year: 2022
  end-page: 601
  ident: CR8
  article-title: Plasma neutralization of the SARS-CoV-2 omicron variant
  publication-title: N. Engl. J. Med.
– volume: 30
  start-page: 880
  year: 2022
  end-page: 886.e884
  ident: CR26
  article-title: SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
  publication-title: Cell Host Microbe
– volume: 455
  start-page: 24
  year: 2018
  end-page: 33
  ident: CR78
  article-title: Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV
  publication-title: J. Immunol. Methods
– volume: 443
  start-page: 33
  year: 2017
  end-page: 44
  ident: CR77
  article-title: Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles
  publication-title: J. Immunol. Methods
– volume: 27
  start-page: 2012
  year: 2021
  end-page: 2024
  ident: CR70
  article-title: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
  publication-title: Nat. Med.
– volume: 184
  start-page: 3936
  year: 2021
  end-page: 3948.e3910
  ident: CR15
  article-title: SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
  publication-title: Cell
– volume: 13
  year: 2022
  ident: CR14
  article-title: Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
  publication-title: Nat. Commun.
– volume: 8
  start-page: ofab143
  year: 2021
  ident: CR23
  article-title: CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants
  publication-title: Open Forum Infect. Dis.
– volume: 7
  start-page: eadf1421
  year: 2022
  ident: CR58
  article-title: SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines
  publication-title: Sci. Immunol.
– ident: CR55
– volume: 376
  start-page: e068632
  year: 2022
  ident: CR60
  article-title: Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
  publication-title: BMJ
– volume: 54
  start-page: 815
  year: 2021
  end-page: 828.e815
  ident: CR32
  article-title: A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus
  publication-title: Immunity
– volume: 185
  start-page: 467
  year: 2022
  end-page: 484.e415
  ident: CR41
  article-title: SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
  publication-title: Cell
– volume: 386
  start-page: 1088
  year: 2022
  end-page: 1091
  ident: CR52
  article-title: SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination
  publication-title: N. Engl. J. Med.
– volume: 13
  year: 2022
  ident: 40960_CR14
  publication-title: Nat. Commun.
– volume: 185
  start-page: 467
  year: 2022
  ident: 40960_CR41
  publication-title: Cell
  doi: 10.1016/j.cell.2021.12.046
– volume: 592
  start-page: 616
  year: 2021
  ident: 40960_CR6
  publication-title: Nature
  doi: 10.1038/s41586-021-03324-6
– volume: 184
  start-page: 3936
  year: 2021
  ident: 40960_CR15
  publication-title: Cell
  doi: 10.1016/j.cell.2021.06.005
– volume: 583
  start-page: 290
  year: 2020
  ident: 40960_CR75
  publication-title: Nature
  doi: 10.1038/s41586-020-2349-y
– volume: 383
  start-page: 2603
  year: 2020
  ident: 40960_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2034577
– volume: 5
  start-page: 520
  year: 2014
  ident: 40960_CR51
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2014.00520
– volume: 366
  start-page: 8
  year: 2011
  ident: 40960_CR80
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2010.12.016
– volume: 54
  start-page: 2143
  year: 2021
  ident: 40960_CR36
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.08.015
– volume: 34
  start-page: 108890
  year: 2021
  ident: 40960_CR7
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2021.108890
– volume: 184
  start-page: 2348
  year: 2021
  ident: 40960_CR10
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.037
– volume: 13
  start-page: e0361721
  year: 2022
  ident: 40960_CR22
  publication-title: mBio
  doi: 10.1128/mbio.03617-21
– volume: 386
  start-page: 117
  year: 2012
  ident: 40960_CR74
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2012.09.007
– volume: 373
  start-page: 1372
  year: 2021
  ident: 40960_CR4
  publication-title: Science
  doi: 10.1126/science.abj4176
– volume: 73
  start-page: 1
  year: 2022
  ident: 40960_CR37
  publication-title: Annu. Rev. Med.
  doi: 10.1146/annurev-med-042420-113838
– volume: 185
  start-page: 860
  year: 2022
  ident: 40960_CR40
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.019
– volume: 27
  start-page: 2032
  year: 2021
  ident: 40960_CR12
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01540-1
– volume: 8
  start-page: ofab143
  year: 2021
  ident: 40960_CR23
  publication-title: Open Forum Infect. Dis.
  doi: 10.1093/ofid/ofab143
– volume: 184
  start-page: 1804
  year: 2021
  ident: 40960_CR27
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.026
– volume: 181
  start-page: 281
  year: 2020
  ident: 40960_CR56
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.058
– volume: 443
  start-page: 33
  year: 2017
  ident: 40960_CR77
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2017.01.010
– volume: 329
  start-page: 856
  year: 2010
  ident: 40960_CR76
  publication-title: Science
  doi: 10.1126/science.1187659
– volume: 184
  start-page: 2372
  year: 2021
  ident: 40960_CR29
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.013
– volume: 383
  start-page: 1920
  year: 2020
  ident: 40960_CR2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2022483
– volume: 596
  start-page: 410
  year: 2021
  ident: 40960_CR17
  publication-title: Nature
  doi: 10.1038/s41586-021-03791-x
– volume: 16
  start-page: e1008764
  year: 2020
  ident: 40960_CR68
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1008764
– volume: 185
  start-page: 847
  year: 2022
  ident: 40960_CR19
  publication-title: Cell
  doi: 10.1016/j.cell.2022.01.015
– volume: 13
  year: 2022
  ident: 40960_CR57
  publication-title: Nat. Commun.
– volume: 13
  start-page: eabi8631
  year: 2021
  ident: 40960_CR48
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abi8631
– volume: 599
  start-page: 465
  year: 2021
  ident: 40960_CR72
  publication-title: Nature
  doi: 10.1038/s41586-021-04017-w
– volume: 12
  start-page: e00281
  year: 2021
  ident: 40960_CR25
  publication-title: mBio
– volume: 310
  start-page: 1510
  year: 2005
  ident: 40960_CR50
  publication-title: Science
  doi: 10.1126/science.1118948
– volume: 384
  start-page: 403
  year: 2021
  ident: 40960_CR1
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2035389
– volume: 30
  start-page: 41
  year: 2022
  ident: 40960_CR33
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.11.006
– volume: 14
  start-page: eabm3151
  year: 2022
  ident: 40960_CR31
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abm3151
– volume: 12
  year: 2021
  ident: 40960_CR43
  publication-title: Nat. Commun.
– volume: 385
  start-page: 1533
  year: 2021
  ident: 40960_CR61
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2113891
– volume: 386
  start-page: 1088
  year: 2022
  ident: 40960_CR52
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2119912
– volume: 593
  start-page: 130
  year: 2021
  ident: 40960_CR9
  publication-title: Nature
  doi: 10.1038/s41586-021-03398-2
– volume: 6
  start-page: 915
  year: 2014
  ident: 40960_CR73
  publication-title: MAbs
  doi: 10.4161/mabs.28808
– volume: 7
  year: 2022
  ident: 40960_CR79
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-022-00459-z
– volume: 55
  start-page: 355
  year: 2022
  ident: 40960_CR35
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.01.001
– volume: 27
  start-page: 717
  year: 2021
  ident: 40960_CR13
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01294-w
– volume: 183
  start-page: 1508
  year: 2020
  ident: 40960_CR11
  publication-title: Cell
  doi: 10.1016/j.cell.2020.10.052
– volume: 26
  start-page: 845
  year: 2020
  ident: 40960_CR44
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0897-1
– volume: 2
  start-page: 100290
  year: 2021
  ident: 40960_CR82
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2021.100290
– volume: 600
  start-page: 523
  year: 2021
  ident: 40960_CR30
  publication-title: Nature
  doi: 10.1038/s41586-021-04085-y
– volume: 6
  start-page: eabj1750
  year: 2021
  ident: 40960_CR18
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abj1750
– volume: 31
  start-page: 107624
  year: 2020
  ident: 40960_CR66
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2020.107624
– volume: 28
  start-page: 1063
  year: 2022
  ident: 40960_CR62
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01753-y
– ident: 40960_CR55
  doi: 10.3389/fmed.2021.628370
– volume: 11
  start-page: 618685
  year: 2021
  ident: 40960_CR81
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.618685
– volume: 24
  start-page: 1590
  year: 2018
  ident: 40960_CR65
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0161-0
– volume: 6
  start-page: 228ra238
  year: 2014
  ident: 40960_CR34
  publication-title: Sci. Transl. Med.
– volume: 455
  start-page: 24
  year: 2018
  ident: 40960_CR78
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2018.01.013
– volume: 595
  start-page: 426
  year: 2021
  ident: 40960_CR42
  publication-title: Nature
  doi: 10.1038/s41586-021-03696-9
– volume: 386
  start-page: 599
  year: 2022
  ident: 40960_CR8
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMc2119641
– volume: 184
  start-page: 2316
  year: 2021
  ident: 40960_CR38
  publication-title: Cell
  doi: 10.1016/j.cell.2021.03.029
– volume: 2
  start-page: 100355
  year: 2021
  ident: 40960_CR16
  publication-title: Cell Rep. Med.
  doi: 10.1016/j.xcrm.2021.100355
– volume: 16
  start-page: e0253487
  year: 2021
  ident: 40960_CR71
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0253487
– volume: 54
  start-page: 815
  year: 2021
  ident: 40960_CR32
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.03.009
– ident: 40960_CR49
  doi: 10.48550/arXiv.1802.03426
– volume: 7
  start-page: eabo3425
  year: 2022
  ident: 40960_CR21
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abo3425
– volume: 5
  start-page: eabe0240
  year: 2020
  ident: 40960_CR45
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abe0240
– volume: 7
  start-page: eadf1421
  year: 2022
  ident: 40960_CR58
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.adf1421
– volume: 473
  start-page: 112630
  year: 2019
  ident: 40960_CR84
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2019.07.002
– volume: 12
  start-page: eabb4757
  year: 2020
  ident: 40960_CR69
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abb4757
– volume: 27
  start-page: 2012
  year: 2021
  ident: 40960_CR70
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01488-2
– volume: 376
  start-page: e068632
  year: 2022
  ident: 40960_CR60
  publication-title: BMJ
– volume: 92
  start-page: e00721
  year: 2018
  ident: 40960_CR67
  publication-title: J. Virol.
– volume: 584
  start-page: 437
  year: 2020
  ident: 40960_CR46
  publication-title: Nature
  doi: 10.1038/s41586-020-2456-9
– volume: 2
  start-page: 100851
  year: 2021
  ident: 40960_CR83
  publication-title: STAR Protoc.
  doi: 10.1016/j.xpro.2021.100851
– volume: 371
  start-page: eabf4063
  year: 2021
  ident: 40960_CR20
  publication-title: Science
  doi: 10.1126/science.abf4063
– volume: 377
  start-page: eabq1841
  year: 2022
  ident: 40960_CR64
  publication-title: Science
  doi: 10.1126/science.abq1841
– volume: 30
  start-page: 880
  year: 2022
  ident: 40960_CR26
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2022.03.029
– volume: 11
  start-page: e75228
  year: 2022
  ident: 40960_CR59
  publication-title: Elife
  doi: 10.7554/eLife.75228
– volume: 29
  start-page: 1137
  year: 2021
  ident: 40960_CR28
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.06.001
– volume: 14
  start-page: eabn7842
  year: 2022
  ident: 40960_CR5
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abn7842
– volume: 375
  start-page: 678
  year: 2022
  ident: 40960_CR53
  publication-title: Science
  doi: 10.1126/science.abn7591
– volume: 369
  start-page: 1501
  year: 2020
  ident: 40960_CR63
  publication-title: Science
  doi: 10.1126/science.abd0826
– volume: 38
  start-page: 110368
  year: 2022
  ident: 40960_CR24
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2022.110368
– volume: 182
  start-page: 828
  year: 2020
  ident: 40960_CR39
  publication-title: Cell
  doi: 10.1016/j.cell.2020.06.025
– volume: 69
  start-page: 769
  year: 2020
  ident: 40960_CR47
  publication-title: MMWR Morb. Mortal. Wkly Rep.
  doi: 10.15585/mmwr.mm6925a1
– volume: 14
  start-page: eabm2311
  year: 2022
  ident: 40960_CR54
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.abm2311
– reference: 36172122 - medRxiv. 2022 Sep 18:2022.09.15.22280000. doi: 10.1101/2022.09.15.22280000
SSID ssj0000391844
Score 2.4476972
Snippet SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to whether other...
Abstract SARS-CoV-2 variants have continuously emerged in the face of effective vaccines. Reduced neutralization against variants raises questions as to...
SourceID doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5171
SubjectTerms 13/106
13/109
13/31
49/1
49/31
49/79
631/250/2152/2153/1291
631/250/255/2514
82/1
Antibodies
Antibody response
At risk populations
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Female
Humanities and Social Sciences
Humans
mRNA
multidisciplinary
Neutralization
Pandemics
Populations
Pregnancy
Pregnancy Complications, Infectious
Recognition
SARS-CoV-2
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Viral diseases
Vulnerable Populations
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFB6kIOqDeO_WKiP4ZkMzt8zksRZLEfTBWulbmDmTYCAky262stAf75lJNu6iVB98C5kLM2e-c5vLOYS89XmVWW1V4vOSJ1LmPEEzxCFfSe8YaF1VYb_j0-fs_FJ-vFJXW6m-wp2wITzwQLhjFOLaalNJ7cIZDxhtQfOsZDZDT8HHYNuoxracqSiDRY6uixxfyaTCHC9llAmootBlQrM9SXc0UQzY_ycr8_fLktOJ6QNyb9XO7fqHbZotpXT2iDwcrUl6MsziMblTtk_I3SG_5Popubk4-XKRnHbfEk6vLUA9bP3Rsqmh7pfULTrrqW09nXdoO_f42deu82s6XPPoFjTovQhN2nfYB8K1xYZdRSG8d1y0tG7p9aoJsatdU2I_m3xgy2fk8uzD19PzZEy3kICSrE-gylMAX1mFBLc59-B0JlPQzDMrWMaZBF6C9Lm2AgTXDlJWoZACw4E5IZ6TvbZry31CK1tWSvnUCy-l0D632MwZz3xqPQg7I2xD-gLGWOQhJUZTxDNxYYphuQpcriIuV5HOyLupzXyIxHFr7fdhRaeaIYp2_IHYKkZsFX_D1owcbvBQjKy9LLhBC1jlxqgZeTMVI1OGkxbblt0q1tFGGKWwixcDfKaRoETnqRB6RswOsHaGulvS1t9j4G90ndFBZTi5ow0Gf43rNlocTTj9B9Id_A_SvST3eeC1FOWwPCR7_WJVvkLzrXevI6f-BHm1QWw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA96IuqD-O3qKRF888o1H23SJzkP10PQB8-TeyvJpD0LpVm33ZMF_3gnbbfnoiy-leaDJPObyWQmmSHktcvK1CiTRC4reCRlxiNUQyzylXSWgVJlGewdnz6nJ2fy43lyPhrc2vFa5UYm9oLaeQg28kOuUfFIMq2Tt4sfUcgaFbyrYwqN6-QG44ik8FJ8_mGysYTo51rK8a1MLPRhK3vJgBsVHpxQeY_irf2oD9v_L13z7yuTk9_0Drm1ahZm_dPU9R9b0_weuTvqlPRoAMF9cq1oHpCbQ5bJ9UPy6_Toy2l07L9FnF4agGowANKirqDqWmqX3jhqGkcXHjXoDj-7ynq3psNlD7-kYffrAUo7j30gaBts6EsK4dXjsqFVQy9XdYhgbesC-9lkBWsfkbP5-6_HJ9GYdCGCRLIugjKLAVxpEoU0zLgDq1IZg2KOGcFSziTwAqTLlBEguLIQsxJFFWgOzArxmOw1vimeElqaokwSFzvhpBTKZQabWe2Yi40DYWaEbZY-hzEieUiMUee9Z1zofCBXjuTKe3Ll8Yy8mdoshngcO2u_CxSdaoZY2v0Pv7zIR9bMUU3AqepSKhu8iKCVAcXTgpkUz6IunZH9DR7ykcHb_AqOM_JqKkbWDP4W0xR-1ddRWugkwS6eDPCZRoJyncdCqBnRW8DaGup2SVN978N_4wEaj6kMJ3ewweDVuHatxcGE0_9Yume7Z_2c3OaBi2KUs3Kf7HXLVfEC1bPOvux58DefiTi3
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA_niagP4rerp0QQX7xq89EmfRA5D49DOB88V-6tJJNWC6Xd63ZPF_zjnfRLF5fDt9J8kGR-k5nJJDOEvHBJHhtlosAlGQ-kTHiAaohFvpLOMlAqz_15x8mn-HguP55FZztkvG47LOByq2nn80nNm_L1z_P1O2T4t_2Tcf1mKTt2R-mD1hBq5EH4cnEe-MRS3gE7ZNm4Qq6isOIe-CeDBdBt1iJBG0cOz2m297YhsrrI_tvU0X9vVU6u1Zvk-qpamPUPU5Z_Sa-j2-TWoHbSgx4nd8hOVt0l1_pElOt75NfpwefT4LD-GnB6YQCK_oyQZmUBRbuktqmNo6ZydFGjkt3iZ1vY2q1pfx-kbqgXkB2GaVtjH4jrChvWOQX_MLKpaFHRi1Xpg1zbMsN-xsRhy_tkfvThy-FxMORlCCCSrA0gT0IAl5tIIZkT7sCqWIagmGNGsJgzCTwD6RJlBAiuLIQsx90MNAdmhXhAdqu6yh4RmpssjyIXOuGkFMolBptZ7ZgLjQNhZoSNS5_CELTc584o0855LnTakytFcqUdudJwRl5NbRZ9yI5La7_3FJ1q-nDb3Y-6-ZYO3JuiJoFT1blU1jsaQSsDiscZMzGaqy6ekb0RD-kI4ZRrVJWjROtoRp5Pxci93iVjqqxedXWUFjqKsIuHPXymkeDWz0Mh1IzoDWBtDHWzpCq-dxHC0cZGS5bh5PZHDP4Z12VrsT_h9D-W7vHls35CbnDPRSFuxXKP7LbNKnuKGlxrn3U8-BtlT0NZ
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_HiagP4rfVUyL45hWbjzbp47l4HII-eJ7cW0kmrRZKu-x271i4P95J-qGLx6FvpcmEJPObZCYzmRDy1uVVZpRJY5eXPJYy5zGqIRblSjrLQKmq8ucdn79kJ2fy03l6vkf4dBcmBO2HlJZhmZ6iw96vZRBp3GHQ4kGtO0Yz_ZZWgvkwvkW2mM9VfMZzLeV4PyYR-hrSnT0opOq_Tr_8O0xy9pXeI3c27dJsL03T_LEdHT8g90c9kh4NPX9I9sr2Ebk9vCy5fUyuTo--nsaL7nvM6YUBqIdDP1o2NdT9mtpVZxw1raPLDrXmHj_72nZuS4cAj25F_Y4XQEn7DttAoLZI2FUU_E3HVUvrll5sGp-12jYltjO9BLZ-Qs6OP35bnMTjQwsxpJL1MVR5AuAqkyrkW84dWJXJBBRzzAiWcSaBlyBdrowAwZWFhFW4PIHmwKwQT8l-27Xlc0IrU1Zp6hInnJRCudwgmdWOucQ4ECYibJr6AsYs5P4xjKYI3nChi4FdBbKrCOwqkoi8m2mWQw6OG2t_8Byda_r82eFHt_pRjHgqUDXAoepKKus9h6CVAcWzkpkM7U-XReRgwkMxCvW64Bp13zTXOo3Im7kYxdH7WExbdptQR2mh0xSbeDbAZ-4JruU8EUJFRO8Aa6eruyVt_TOk_EajGU1ThoM7nDD4u183zcXhjNN_mLoX_9f6S3KXe6lKcK2VB2S_X23KV6ii9fZ1kMlfLjg2TA
  priority: 102
  providerName: Springer Nature
Title SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations
URI https://link.springer.com/article/10.1038/s41467-023-40960-0
https://www.ncbi.nlm.nih.gov/pubmed/37620337
https://www.proquest.com/docview/2856659885
https://www.proquest.com/docview/2857838556
https://pubmed.ncbi.nlm.nih.gov/PMC10449910
https://www.nature.com/articles/s41467-023-40960-0.pdf
https://doaj.org/article/cee7a78f47b5458c87ac726e1a6998d6
UnpaywallVersion publishedVersion
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: KQ8
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Open Access Full Text
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: DOA
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Inspec with Full Text
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: ADMLS
  dateStart: 20121101
  isFulltext: true
  titleUrlDefault: https://www.ebsco.com/products/research-databases/inspec-full-text
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: DIK
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: RPM
  dateStart: 20120101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVAQT
  databaseName: Springer Nature - nature.com Journals - Fully Open Access
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: NAO
  dateStart: 20101201
  isFulltext: true
  titleUrlDefault: https://www.nature.com/siteindex/index.html
  providerName: Nature Publishing
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: 7X7
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central (ProQuest)
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: BENPR
  dateStart: 20190101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Technology Collection
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: 8FG
  dateStart: 20100401
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/technologycollection1
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: M48
  dateStart: 20101001
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: AAJSJ
  dateStart: 20101201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 2041-1723
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000391844
  issn: 2041-1723
  databaseCode: C6C
  dateStart: 20101201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1rb9Mw0NpaIeAD70dhVEbiG0uJH4mdj121MlVaNa0UxqfIsROIiJKqTYeK-PGc8ygUpol9SaLkbNmXe9l3vkPojQkSXwnlOSaIqcN5QB0wQyLgK24iooVIErvfcTr1T-Z8cuFd7CG_PQtTBe1XKS0rMd1Gh71b8YqlQcPAigesbscdLEyyj7q-dSx1UHc-PRt-tpXkXE4c0MqsOSHjMnlF4x0tVCXrv8rC_DdQcustvYtur_OF2nxXWfaHQhrfR5_aqdRxKN8G6zIa6B9_ZXm8-VwfoHuNjYqHNeRDtBfnj9Ctumrl5jH6ORuez5xR8dGh-FJpndYbijjOUp2WKxwtC2Wwyg1eFGCRl_BYplFhNrgOHimW2GrTiuBxWUAfwAQ5NCwSrO0pymWO0xxfrjObETvKYuinrTK2eoLm4-MPoxOnKeLgaI-T0tFJ4GptEuUJoImAGh0Jn7taEEMUIz4lXNNYcxMIxTSjItIuSUD0aUk1iRh7ijp5kcfPEU5UnHiecQ0znDNhAgXNImmIcZXRTPUQaX9qqJsM57bQRhZWnnYmwxqzIWA2rDAbuj30dttmUef3uBb6yNLKFtLm5q5eFMsvYfP_QjA7YKoy4SKyXkkthdKC-jFRPqxtjd9DBy2lhY3AWIVUgl3tBVJ6PfR6-xlY3fpvVB4X6wpGSCY9D7p4VhPmdiSgJ6jLmOghuUOyO0Pd_ZKnX6t04rAgh2UvgckdttT9e1zX4eJwywH_gboXNwN_ie5QywAuyHF-gDrlch2_AvOvjPpoX1wIuMrx-z7qDoeT2QTuR8fTs3N4O_JH_WpjBa6nXPYbyfALTRVdVA
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtQw1KqKUOGA2AkUMBKcaFRviZ0DQqVQTelyoC2aW-rYCUSKkmEm02okvolv5DlbGYFGXHqL4kW23_6e_R5Cr22UhVrqwLdRynwhIuaDGpIAXQmbUCNlljl_x9FxODoTn8fBeA396t_CuGuVPU9sGLWtjPORbzMFikcQKRW8n_zwXdUoF13tS2i0aHGQLi7BZJu92_8I8H3D2N6n092R31UV8E0gaO2bLCLG2EwHEhYZMWsSGQpiJLVUcxoyKgxLjbCR1NxwJhNDaAa0aBQzNHEOUGD5NwQnwuXql2M5-HRctnUlRPc2h3C1PRMNJwLBCIYaGAs-WZJ_TZmAf-m2f1_RHOK0t9HGvJzoxaUuij9E4d5ddKfTYfFOi3T30Fpa3kc326qWiwfo58nOlxN_t_rqM3yhjclbhyNOi9zk9Qwn00pbrEuLJxVo7DV81nlS2QVuL5dUU-ykbUMQuK5gDiCSEgZWGTbuleW0xHmJL-aFy5idFCnM01chmz1EZ9cCjkdovazK9AnCmU6zILDEcisElzbSMCxRllqireHaQ7Q_-th0GdBdIY4ibiLxXMUtuGIAV9yAKyYeejuMmbT5P1b2_uAgOvR0ububH9X0W9yxghjUEtiqyoRMXNTSKKmNZGFKdQi2rw09tNnjQ9wxlFl8hf4eejU0Aytw8R1dptW86SMVV0EAUzxu0WdYCcgRRjiXHlJLiLW01OWWMv_epBsHgx3MYgqb2-px8Gpdq85ia8DT_zi6p6t3_RJtjE6PDuPD_eODZ-gWcxRFgMeLTbReT-fpc1AN6-RFQ48YnV83A_gNalx2Tw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtQw1KqK2A6InUABI8GJRhMviZ0DQqVl1FKoEKVobsaxE4gUJcNMptVIfBlfx3O2MgKNuPQ2mtiW7bcvfg-h5zbOIi106Ns4pT7nMfVBDUmArrhNiBEiy5y_48NRtH_C303CyQb61b-FcWmVPU9sGLWtjPORj6gExSOMpQxHWZcW8XFv_Hr6w3cdpFyktW-n0aLIYbo8A_Nt_upgD2D9gtLx28-7-37XYcA3ISe1b7I4MMZmOhSw4Zhak4iIB0YQSzQjESXc0NRwGwvNDKMiMQHJgC6NpIYkzhkK7P-SYJy5dDIxEYN_x1Vel5x373QCJkdz3nAlEJJgtIHh4AcrsrBpGfAvPffvdM0hZnsdXV2UU70800Xxh1gc30Q3On0W77QIeAttpOVtdLntcLm8g34e73w69nerLz7Fp9qYvHU-4rTITV7PcTKrtMW6tHhagfZew886Tyq7xG2iSTXDTvI2xIHrCtYAgilhYpVh415czkqcl_h0Ubjq2UmRwjp9R7L5XXRyIeC4hzbLqkwfIJzpNAtDG1hmOWfCxhqmJdISG2hrmPYQ6a9ema4aumvKUagmKs-kasGlAFyqAZcKPPRymDNta4GsHf3GQXQY6ep4N39Us2-qYwsKVBQ4qsy4SFwE00ihjaBRSnQEdrCNPLTV44PqmMtcnZOCh54Nn4EtuFiPLtNq0YwRkskwhCXut-gz7ARkCg0YEx6SK4i1stXVL2X-vSk9DsY7mMgEDrfd4-D5vtbdxfaAp_9xdQ_Xn_opugKkr94fHB0-QteoI6gA2D3fQpv1bJE-Bi2xTp405IjR14um_98HB3qK
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1rb9QwLBo3IcYH3o-DgYLEN9Zb82iTfjwmpgmJCTEOxqcqjxaqVe3prjd0iB-Pkz7gYJrYt6pxosSxYzt2bIRe2iSPlVBRYJOMBpwnNAA1RANfcauJESLP3X3Hu-P4aMbfnkanWyju38L4oH2f0tIf03102P6Se5YGCQMWD2jdQTiZ2_wa2o6dY2mEtmfH76dfXCW5kJMApDLrXsiETF7QeUMK-WT9F2mY_wZKDt7Sm-jGqpqr9XdVln8IpMPb6HO_lDYO5WyyavTE_Pgry-PV13oH3ep0VDxtIe-iray6h663VSvX99HPk-mHk-Cg_hRQfK6MKdoLRZyVhSmaJdaLWlmsKovnNWjkDXw2ha7tGrfBI_UCO2nqCR43NYwBTFBBxzrHxr2iXFS4qPD5qnQZsXWZwTh9lbHlAzQ7fPPx4CjoijgEJuKkCUyehMbYXEUCaCKh1mgR89AIYoliJKaEG5oZbhOhmGFUaBOSHI4-I6khmrGHaFTVVfYY4VxleRTZ0DLLORM2UdBNS0tsqKxhaoxIv6mp6TKcu0IbZeo97UymLWZTwGzqMZuGY_Rq6DNv83tcCv3a0coA6XJz-x_14mva7V8KagcsVeZcaOeVNFIoI2icERWDbWvjMdrtKS3tDoxlSiXo1VEiZTRGL4ZmYHXnv1FVVq88jJBMRhEM8aglzGEmICdoyJgYI7lBshtT3Wypim8-nTgY5GD2EljcXk_dv-d1GS72Bg74D9Q9uRr4U7RDHQOEcI7zXTRqFqvsGah_jX7e8fovSJ9VtQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+vaccination+elicits+broad+and+potent+antibody+effector+functions+to+variants+of+concern+in+vulnerable+populations&rft.jtitle=Nature+communications&rft.au=Hederman%2C+Andrew+P&rft.au=Natarajan%2C+Harini&rft.au=Heyndrickx%2C+Leo&rft.au=Ari%C3%ABn%2C+Kevin+K&rft.date=2023-08-24&rft.pub=Nature+Publishing+Group&rft.eissn=2041-1723&rft.volume=14&rft.issue=1&rft.spage=5171&rft_id=info:doi/10.1038%2Fs41467-023-40960-0&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon